Why it matters:
FMR occurs when the left atrium or left ventricle of the heart dilates, causing the mitral valve annulus to also dilate and prevent the mitral valve leaflets from properly closing.
The Carillon System is designed to treat the primary cause of FMR in patients and is the first and only device to demonstrate a reduction in regurgitant volume and favourable left ventricular remodelling.
How it works:
The implantable device consists of a proximal anchor and a distal anchor connected by a shaping ribbon.
Utilising the proximity of the coronary sinus to the mitral annular apparatus, the device is designed to reduce mitral annulus dilatation upon deployment, thereby reducing functional mitral regurgitation (FMR).
The implant is inserted through a catheter and hence requires no surgical procedure.
Ask the expert:
Gregory D. Casciaro, President and CEO of Cardiac Dimensions Inc.
“It was not long ago that surgical intervention was the final solution to treating FMR. We are now part of a new paradigm of minimally invasive care that can safely and effectively treat FMR in a wide range of patients. Because the Carillon System preserves mitral valve leaflet integrity, patients can be treated earlier in the highly progressive disease cycle.”
Cardiac Dimensions Inc is a leader in the development of innovative, minimally invasive treatments to address heart failure and related cardiovascular conditions.
For more information, visit www.cardiacdimensions.com.